Q2 FY2026 EarningsQ2 FY26 reported a revenue beat of $238.9M vs. $222.6M consensus (+7.36%), driven by the successful closing of the Astellas collaboration and recognition of a $239.3M upfront payment. However, GAAP Diluted EPS of $0.47 missed the $0.66 consensus by 28.5% due to a $48.0M pass-through R&D payment to Sanofi and significant share dilution (+27.5M shares YoY). The company maintains a robust cash position of $1.01B, with a critical Phase 3 ECLIPSE 1 data catalyst expected in Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Vir Biotechnology(VIR) the Revenue is 238.95 M (+196 times%), Beat estimate;the EBIT is 73.47 M (+162%), Miss estimate;the EPS is 0.47 (+158.8%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.24B19582.54%
0.22B18233.61%
+0.02B1,348.93%
EBITMiss expectations
0.07B162.04%
0.08B164.25%
-0.00B2.21%
EPSMiss expectations
0.47158.75%
0.6575182.19%
-0.187523.44%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf